Castle Biosciences, Inc. (CSTL)

Castle Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	343.53	332.07	219.79	137.04	94.09	62.65
Revenue Growth (YoY)	10.15%	51.09%	60.38%	45.65%	50.18%	20.79%
Cost of Revenue	68.9	60.21	44.98	32.01	15.82	9.69
Gross Profit	274.63	271.86	174.81	105.03	78.26	52.96
Selling, General & Admin	222.56	200.05	180.15	143	86.74	48.13
Research & Development	50.11	52.04	53.62	44.9	29.65	13.26
Amortization of Goodwill & Intangibles	16.8	11.11	9.01	8.27	1.96	-
Operating Expenses	289.47	263.19	242.78	196.17	118.34	61.39
Operating Income	-14.83	8.67	-67.98	-91.14	-40.08	-8.42
Interest Expense	-0.15	-0.58	-0.01	-0.02	-0	-2.63
Interest & Investment Income	12.25	12.92	10.62	3.97	0.07	0.37
Other Non Operating Income (Expenses)	0.05	-	-	-	-	-
EBT Excluding Unusual Items	-2.69	21.01	-57.37	-87.19	-40.01	-10.69
Gain (Loss) on Sale of Investments	3.88	0.56	-	-	-	-
Other Unusual Items	-	-	-	18.29	-	0.49
Pretax Income	-18.92	21.56	-57.37	-68.9	-40.01	-10.2
Income Tax Expense	-6.68	3.32	0.1	-1.77	-8.72	0.08
Net Income	-12.24	18.25	-57.47	-67.14	-31.29	-10.28
Net Income to Common	-12.24	18.25	-57.47	-67.14	-31.29	-10.28
Shares Outstanding (Basic)	29	28	27	26	25	19
Shares Outstanding (Diluted)	29	29	27	26	25	19
Shares Change (YoY)	1.04%	9.15%	2.87%	3.65%	32.80%	118.63%
EPS (Basic)	-0.43	0.66	-2.14	-2.58	-1.24	-0.54
EPS (Diluted)	-0.43	0.62	-2.14	-2.58	-1.24	-0.54
Free Cash Flow	25.38	36.54	-19.25	-47.29	-22.47	5.11
Free Cash Flow Per Share	0.89	1.25	-0.72	-1.81	-0.89	0.27
Gross Margin	79.94%	81.87%	79.53%	76.64%	83.18%	84.54%
Operating Margin	-4.32%	2.61%	-30.93%	-66.51%	-42.60%	-13.45%
Profit Margin	-3.56%	5.49%	-26.15%	-48.99%	-33.26%	-16.41%
Free Cash Flow Margin	7.39%	11.00%	-8.76%	-34.51%	-23.88%	8.16%
EBITDA	7.83	24.67	-55.65	-80.6	-36.67	-7.95
EBITDA Margin	2.28%	7.43%	-25.32%	-58.81%	-38.98%	-12.69%
D&A For EBITDA	22.66	16	12.33	10.54	3.41	0.47
EBIT	-14.83	8.67	-67.98	-91.14	-40.08	-8.42
EBIT Margin	-4.32%	2.61%	-30.93%	-66.51%	-42.60%	-13.45%
Effective Tax Rate	-	15.39%	-	-	-	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q